Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$276.00M+33.33%Company Profile
- CEO
- Mark Crossley
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,000
- Beta
- -0.06
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.80
Financials
INVVY has only 6 quarterly periods on file — the charts below show the full history available.
Revenue
$276.00M+33.3%Net Income
$39.00M-4.9%EBITDA
$86.00M+45.8%Free Cash Flow
$-20.00MEPS (diluted)
$0.28+0.0%Shares Outstanding (diluted)
140.99M-3.6%Operating Expenses
$157.00MCash & Debt
$689.00MReturn of Capital
$0.00Dividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $901.00M | $-53.00M | $-0.36 |
| 2021 | $791.00M | $205.00M | $1.41 |
| 2020 | $647.00M | $-148.00M | $-0.96 |
| 2019 | $785.00M | $134.00M | $0.90 |
Valuation
INVVYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105+31.25%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·11d ago·Neutral
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration w
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (such holders, the “Spec
View source ↗ - Newsbusinesswire.com·38d ago·Negative
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here
View source ↗ - Newszacks.com·45d ago·Negative
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
View source ↗
Congress trades
No disclosed congressional trades in INVVY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.